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Abstract
Background: The nucleolus is a multi-domain enriched with proteins involved in ribosome biogenesis, cell cycle
and apoptosis control, viral replication and differentiation of stem cells. Several authors have suggested a role for
the nucleolus also in malignant transformation. We have recently demonstrated that under specific circumstances
the transcriptional factor EGR1 is shuttled to the nucleolus where it functions as a negative regulator of RNA
polymerase I. Since this activity is hampered in ARF −/− cells, and ARF transcription is regulated by EGR1 while the
turnover of ARF protein is under the control of B23, we speculated that some sort of cooperation between EGR1
and B23 might also exist.
Results: In this work we identified a canonical EGR1 binding site on the B23 promoter through experiments of
transactivation and in vitro DNA binding assay. We then found that the levels of B23 expression are directly
correlated with those of EGR1, and that this correlation applies to several cellular types and to different stress
conditions. Furthermore, we showed that EGR1 stability and accumulation within the nucleolus is in turn regulated
by B23 through proteasome involvement, similarly to ARF turnover.
Conclusion: Our results highlight EGR1 as a regulator of B23 expression actively playing within the newly
discovered nucleolar B23-ARF-EGR1 network.
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Background
During tumorigenesis, cancer cells increase the produc-
tion of ribosomes to support the higher rate of protein
synthesis associated with cancer growth. This is supported
by the increase in rRNA synthesis transcribed in the nu-
cleolus by RNA polymerase I, and correlates with adverse
prognosis [1–3]. To contrast this mechanism, the prod-
ucts of Rb and p53, two important tumour suppressor
genes, negatively interfere with the RNA polymerase I and
the assembly of the transcriptional machinery on the
rDNA promoter [4, 5]. p53 activation is under direct
control of the negative regulator MDM2, which in turn
is inactivated by ARF. This explains why ARF is pivotal
for triggering the cell-cycle arrest and the apoptotic
programme after oncogenic cues [6]. The stability of ARF
is significantly increased in cells that overexpress exogen-
ous B23 (known also as nucleophosmin, numatrim, and
NOR38). B23 associates with ARF within the nucleolus,
delaying its turnover. As a consequence, the inhibition of
B23 by shRNA has destabilizing effects over ARF [7]. ARF
mutants unable to bind B23 are unstable and functionally
impaired [8]. In mouse embryonic fibroblasts (MEFs) lack-
ing both B23 and p53, ARF is mainly found outside the
nucleolus and with a shortened half-life, conferring the
cells with higher proliferation rates [9]. B23 is an abun-
dant, multifunctional protein present at high amount in
the granular region of nucleoli [10]. It is involved in the
regulation of ribosome biogenesis, and the control of
genome stability and survival in response to a variety of
stress stimuli [11–13]. In fact, B23 −/− fibroblasts become
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aneuploid and have increased levels of P53 in a stable
form [7]. Conversely, B23 has been shown to induce
senescence in normal primary fibroblasts [14] and its
overexpression in tumors lacking p53 is known to pro-
mote proliferation [15]. The transcription factor EGR1
(early growth response protein 1) is involved in the
transcriptional regulation of responses to a wide num-
ber of proliferative, differentiation and stress stimuli
[16, 17]. In particular, EGR1 regulates the expression of
key genes, including p53, TGFB, CDKN1A/p21 and
PTEN, involved in the growth and division of cancer
cells, [18–20]. Egr-1 +/− and Egr-1 −/− MEFs bypass sen-
escence and grow as typically immortalized cells. Besides
to cover the role as “gatekeeper” of p53-dependent growth
regulatory mechanisms [18], EGR1 has been suggested to
play a role as tumour suppressor in several tumor types
[21–23]. We have recently demonstrated that EGR1 be-
haves as a negative regulator of RNA polymerase I [24].
EGR1 localizes to the nucleolus and the more it is
expressed the less is the 47S pre-rRNA synthesized. ARF
is required for the nucleolar localization of EGR1. Indeed,
in cells ARF −/− such as the NIH-3 T3 Egr1 does not keep
the nucleolar localization and the ability to suppress the
synthesis of the 47S ribosomal precursor [24]. In view of
the functional interaction of ARF with B23, and the fact
that EGR1 regulates the transcription of ARF [25] we have
hypothesized that EGR1 might extend its control also on
B23 expression. Here, we show that EGR1 promotes its
stability and the transcription of B23 gene.
Results
The expression of nucleolar B23 correlates with the levels
of EGR1
To verify our hypothesis we first monitored the effects
on the expression of B23 in HeLa cells by either increas-
ing or reducing the levels of EGR1. After transient trans-
fection of the pEGFP-EGR1 expression vector, showed a
six-fold increase of B23 mRNA in low serum conditions
(Fig. 1a). No changes were observed under culture con-
ditions with 10 % FBS. Accordingly, lowering the EGR1
mRNA levels with siRNA specific to EGR1 sequence, we
observed a significant reduction of B23 mRNA levels
compared to cells treated with non-specific (scrambled)
siRNA (Fig. 1d upper panel). Here again, the inhibitory
effect on B23 mRNA synthesis was observed only in
cells cultured in low serum conditions, and not in pres-
ence of 10 % FBS. Similar changes were observed with
the B23 protein synthesis under the same experimental
conditions. In summary, in condition of serum deprivation
the B23 mRNA and protein levels increased after EGR1
overexpression and decreased after EGR1 silencing.
To verify that the above results in HeLa cells are not
dependent upon the specific cellular context, we repli-
cated the experiments with a primary culture of human
lung tumor and a glioblastoma derived established cell
line, U87MG and 293 T (Additional file 1: Figure S1). In
all these cultures the B23 mRNA and protein underwent
variations in their levels similar to those observed in
HeLa under the same experimental conditions. We
conclude that the levels of B23 expression are strongly
influenced by EGR1 under lower FBS concentration, a
known stress inducing condition.
To investigate whether EGR1 can influence the expres-
sion of B23 under different stress conditions, we sought
to examine their response to actinomycin D, a genotoxic
agent known to inhibit the RNA Polymerase I and II
activity and to induce DNA damage [26]. The levels of
EGR1 and B23 mRNA and protein showed a step-wise
increase when cells were treated with increasing concen-
trations (0.04, 0.5, and 1 μg/ml) of actinomycin D
(Fig. 2a-b-e-f-g). Also the expression of p300, a specific
EGR1 target gene, increases, whereas the synthesis of
47S and 45S is strongly inhibited, as shown in Fig. 2c-d.
Pre-treatment with EGR1 silencing siRNA abolished the
response of B23 and p300 genes and restored the pro-
duction of 47S rRNA (Fig. 2c-d). Finally, we asked the
question of whether the B23 protein would translocate
to the nucleoplasm in response to Pol I-induced tran-
scription repression, as suggested by Yao Z. et al. [27].
We confirm that in our experimental conditions actino-
mycin D causes the translocation of B23 to the nucleo-
plasm (Additional file 2: Figure S2).
EGR1 binds to B23 promoter
Since the levels of B23 expression vary in response to
EGR1, we hypothesized that as a transcriptional regulator
it might control the B23 expression by interacting with
the promoter. To verify this hypothesis, we first searched
the B23 promoter (NCBI, Accession: NG_016018) for the
presence of canonical sequences that were recognized and
bound by-EGR1.
By-bioinformatics-approach (http://bip.weizmann.ac.il/
index.html) one of such elements was found at −172 bp
to the TATA box (Fig. 3a). To establish the function of
the putative EGR1 binding site, we cloned a partial se-
quence of the B23 promoter (4328 to 5240 bp) from
HeLa DNA and inserted into a luciferase reporter gene
to assay the responsiveness to the activity of EGR1. As
above, EGR1 was exogenously expressed following tran-
sient transfection of the pEGFP-EGR1 expression vector.
All experiments were carried out in HeLa cells cultured
in low serum conditions (0.2 % FBS). The B23 minimal
promoter carrying the sequence of the EGR1 binding
site found in HeLa was successfully transactivated by the
exogenously expressed EGR1, providing high levels of
luciferase activity (Fig. 3b). No luciferase activity was de-
tected when the B23 minimal promoter was deleted of
the sequence or carried a mutated version of the EGR1
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binding site and tested in the same conditions as above
(Fig. 3a-b).
In vitro DNA binding assays were performed to estab-
lish whether EGR1 specifically associated with the min-
imal B23 promoter. We incubated DNA fragments of
the promoter sequence with anti-EGR1 antibody in pres-
ence of extracts of HeLa cells either transfected with full
length EGR1 or EGFP [24]. Cells were cultured either in
low serum conditions or at 10 % FBS. An abundant
(about twenty-fold) enrichment of promoter sequences
was obtained by RT-qPCR (Fig. 3c-d) and PCR (Additional
file 3: Figure S3) only with extracts of cells transfected
with EGR1 and cultured in low serum. No statistically sig-
nificant differences were detected in 10 % FBS. Further-
more, when the PCR was performed with oligonucleotides
specific for a region located upstream the minimal B23
promoter no amplification products were obtained (data
not shown).
B23 expression is downregulated in the brain of
Egr1 −/− mice
In order to gain further evidence about the role of
EGR1 as a regulator of B23 expression, we compared
the levels of B23 mRNA and protein from brain of
Egr1 −/− with Egr1 +/+ mice. Since EGR1 is present
at high levels in mouse and human brain [28] but
not, the levels of B23 expression should likely be different
in the brain of wild-type compared to Egr1 −/− mice, in
case B23 were regulated by EGR1. A significant reduction
of B23 mRNA and protein was detected in the brain of
Egr1 −/− mice (Fig. 4).
Fig. 1 B23 levels are directly correlated to EGR1 under serum deprivation. EGR1 and B23 expression in HeLa cells transfected with a GFP fused full
length EGR1 (named EGR1-GFP) or incubated with siRNA specific for EGR1 (named siRNA EGR1). A control empty vector for GFP (named GFP) or a
scrambled sequence of the siRNA EGR1 (named siRNA SCRAMBLED) were used for comparison, respectively. Experiments were carried out in medium
with either 0.2 % or 10 % FCS. Relative levels of B23 and EGR1 mRNA were quantitated by RT-qPCR in cells transfected with EGR1-GFP or control GFP
(Panel a), and in cells incubated with siRNA EGR1 or control siRNA scrambled (Panel d). Protein signal ratios of EGR1 and B23 to GAPDH were
quantitated by densitometry in cells transfected with EGR1-GFP or control GFP (Panel c), and in cells incubated with siRNA EGR1 or control siRNA
scrambled (Panel f), limitedly to serum deprived conditions. Immunoblot of EGR1 and B23 proteins from a representative experiment (Panel b and e).
Data are the mean +/− s.e. of three independent experiments. Comparisons were performed by t-test. Significant results are highlighted with asterisks
(*p < 0.05; **p < 0.01; ***p < 0.001)
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B23 increases the EGR1 steady-state level of expression
B23 plays an important role in cell growth by regulating
the function of proteins such as ARF and p53 [29]. This
is accomplished by delaying the turnover of these pro-
teins, thus contributing to the activation of suppressor
activities aimed to the control of cell cycle. In the case
of ARF, a physical interaction with B23 has been demon-
strated which protected ARF from proteasomal degrad-
ation [29]. We asked the question of whether a similar
interaction might exist also between EGR1 and B23. If
B23 stabilizes EGR1, then a fall in the B23 synthesis
would likely translate into a change in the detectable
levels of EGR1, due to a loss of stability. To test this hy-
pothesis, we treated the HeLa cells with 30nM B23 spe-
cific siRNA, and monitored the expression of both genes
EGR1 and B23. We show that following a decrease of
B23 mRNA and protein, the levels of EGR1 mRNA
remained unchanged (Fig. 5c). However, the levels of
EGR1 protein detected by immunoblotting were signifi-
cantly lower (Fig. 5a-b). We also confirm that under the
same experimental conditions the level of 47S pre-rRNA
increased whereas the level of p300 diminished, both
significantly (Fig. 5d-e). To investigate whether the lower
levels of EGR1 protein following B23 silencing were the
result of a proteasome-dependent degradation, we tested
in HeLa cells the effect of the proteasome inhibitor MG-
132 (at the concentration of 10 μM) on the stability of
EGR1 during B23 silencing after 16, 20, and 24 h. Only
after 16 h from the treatment the levels of EGR1 did ac-
tually increase (Fig. 5f-g). These experiments clearly sug-
gest the partial involvement of proteasome machinery
on EGR1 turnover, and that, EGR1 stability and accumu-
lation within the nucleolus is likely regulated by B23.
Discussion
B23 (also known as NPM1, nucleophosmin, nucleoplas-
min, NO38, and numatrin) is the best studied member
of the NPM family of chaperones, a highly conserved
protein found in humans, rodents, chicken and fish. Hu-
man B23 is mapped to chromosome 5q35 and is made
up of 12 exons. B23, first isolated from Xenopus laevis
oocyte extracts [30] is a histone storage protein affecting
many intracellular processes such as: i) the rate of ribo-
some synthesis by binding to pre-ribosomal complexes;
ii) DNA duplication and transcriptional regulation; iii)
nucleo-cytoplasmic shuttling and assistance to small
basic proteins such as REV, REX, TAT and p120 for
transport to the nucleolus [31–34]. Within the nucleolus,
Fig. 2 Actinomycin D induces EGR1 and B23. Relative mRNA levels of EGR1, B23, 47S,45S pre-rRNA and p300 (the last two are known gene targets
of EGR1) expressed in HeLa cells treated with Actinomycin D for 1 h at 37 ° C (Panel a to d). The smaller inserts in the panels compare the effect of
siRNA EGR1 plus Actinomycin D to that of Actinomycin D alone. Quantitative evaluation of EGR1 and B23 proteins under the effect of Actinomycin D,
together with a representative immunoblot, are shown in Panel e to g. Data are the mean +/− s.e. of three independent experiments. Comparisons
were performed by one way ANOVA. Significant results are highlighted with asterisks (*p < 0.05; **p < 0.01; ***p < 0.001)
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B23 binds to ARF. The interaction with B23 increases
ARF stability by interfering with the action of the
ubiquitin-proteasome system.
In a recent publication, we have shown that the tran-
scriptional factor EGR1 also localizes to the nucleolus and
acts as negative regulator of RNA polymerase I activity,
similarly to p53 [24]. Both B23 and EGR1 are activated
and expressed under at least two different stress stimuli,
i.e., after UV exposure and H2O2 treatment [35, 36]. We
do not know whether the two genes are independently.
To investigate this hypothesis, we conducted a series of
experiments where HeLa cells grown in serum deprived
conditions and treated either to express high levels of
exogenous EGR1 or to silence the expression of the en-
dogenous EGR1 gene, were examined for changes in the
localization and the expression of B23 mRNA and protein,
and in the regulation of 47S and 45S pre-rRNA synthesis.
The above results show that both pre-rRNAs (47S and
Fig. 4 B23 is downregulated in EGR1 −/− mouse brain. a B23 mRNA and b-c protein levels in EGR1 +/+ and EGR1 −/− mice. Whole brain extracts
(80 μg) were obtained from nine wt and EGR1 −/− female three month old mice. The EGR1 protein was quantified as relative to that of GAPDH taken
as control. Comparisons were performed by t-test. Significant results are highlighted with asterisks (**p < 0.001)
Fig. 3 Identification of the EGR1-binding sequence required for B23 promoter induction. a The human B23 promoter sequence, partial. An EGR1
binding motif is underlined at position −172 from the TATA box. A schematic representation of the WT sequence of B23 promoter and a copy
with a mutated EGR1 binding site cloned upstream of Renilla luciferase gene (pB23-Luc, pB23-mut-Luc). b The luciferase assay in HeLa cells transfected
with EGR1-GFP or the control GFP in combination with either of the two luciferase vectors (pB23-Luc or pB23-mut-Luc) plus a beta-galactosidase vector
for normalization of transfection efficiency. All experiments were done under serum deprivation conditions. c Real time PCR of HeLa cells extracts either
transfected with full length EGR1 or control GFP were incubated with DNA fragments amplified from the promoter sequence of B23 gene, in presence
or absence of anti-EGR1 antibody
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Fig. 5 EGR1 protein level is linked to B23. Analysis of EGR1 after B23 siRNA in HeLa cells grown at 0.2 % FBS. a Immunoblotting of EGR1 and B23
in whole extracts of HeLa cells after B23 siRNA. EGR1 protein significantly decreases following endogenous B23 silencing at 30 nM. b-c-d-e Real
time PCR analysis of B23, EGR1, p300 mRNA and 47S pre-rRNA under B23 silencing. The level of expression of EGR1 remained unchanged (c). As
expected p300 mRNA decrease (d) while the 47S rRNA levels increase levels (e). f-g Immunoblotting of EGR1 under MG-132 treatment after
B23 siRNA for 16, 20 and 24 h. The level of EGR1 protein is restored during B23 silencing after treatment with proteosome inhibitor at 10 μM
for 16 h at 37 ° C. Comparison tests were performed by one way ANOVA and significant results are highlighted with asterisks (*p < 0.05;
**p < 0.01; ***p < 0.001)
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45S) have a rise in their levels when EGR1 is silenced.
Though very preliminar this observation leading us to
hypothesize that the regulation of 47S could be not an
abortive transcription. However, further investigations will
help us to clarify this point. Here we show that in HeLa
cells the levels of B23 mRNA and protein increase after
EGR1 overexpression, and decrease after EGR1 silencing.
We know that this correlation is not cell specific. In fact,
very similar results were obtained also with established gli-
oma cell line and a primary culture of lung adenocarcin-
oma. In addition, the same effect can be assumed in vivo
for the brain of B23 by comparing the expression levels of
B23 in the brain of EGR1 −/− with that from EGR1 +/+
mice. An investigation of the human and mouse B23
promoter nucleotide sequence allowed the recognition
of a potential EGR1 binding site, which proved to be
effective in a reporter gene transactivation assay. The as-
sociation of EGR1 to the B23 promoter was further dem-
onstrated by chromatin immunoprecipitation (ChIP). It
has been shown that following DNA damage B23 binds to
chromatin [37] and to other proteins as well, such as
GADD45 [38], the retinoblastoma protein pRB [39],
PARP1 and PARP2 [40]. They are all intimately linked to
the maintenance of DNA structure, replication or repair.
Following treatment with actinomycin D, nucleolar B23
protein undergoes a rapid translocation to the nucleo-
plasm [41]. Here we confirm these data and find that the
levels of both EGR1 and B23 increase with different con-
centrations of the drug. However, if cells are treated under
conditions inhibiting the expression of EGR1, then the
levels of B23 remain constant. One of the mechanism of
actinomycin D is inhibit the transcription by intercalating
with DNA, in particular at the GC-rich RNA Polymerase I
genes. In our experiments EGR1 seem to facilitate the
action of genotoxic drug. We have already demonstrate in
a previous paper that EGR1 bind UBF protein and the for-
mation of this proteins complex could help the action of
Actinomycin D on the inhibition of RNA Polymerase I
gene. This is only one of the possible scenario further
experiments will help to clarify the role of EGR1 under ac-
tinomycin action. These data further suggest a direct role
for EGR1 in regulating the expression of B23, and that the
correlation between EGR1 and B23 is maintained under
several conditions of cellular stress. Several studies have
demonstrated the involvement of B23 in the p53 tumor
suppressor pathway. Colombo et al. found that B23 when
overexpressed promotes cellular senescence in fibroblasts
and regulates the stability of p53 through direct inter-
action [14]. Further, in response to nucleolar stress, B23
does promote the stabilization of ARF protein [25]. In
view of the multiple interactions that link B23 to the
above molecules and likely to EGR1, we finally studied the
effects of B23 over EGR1. Indeed, by inhibiting the expres-
sion of B23 we observed a reduction of EGR1 protein
levels but not of EGR1 mRNA. Since MG-132, a pro-
teosomal inhibitor, can reduce this effect we speculate
that B23 might have a role for keeping adequate levels of
the intracellular concentration of EGR1 following stress
conditions.
Conclusion
In summary, these findings provide the evidence that
B23 is regulated by EGR1 under stress conditions, and
highlights EGR1 as an important link of the ARF-B23-
rRNA nucleolar network [42], regulating ribosome bio-
genesis and promoting growth arrest.
Methods
Cell lines, primary tumour cell and mice
The cell lines, uterine cervix cancer HeLa (ATCC CCL2),
human embryonic kidney 293 T (ATCC CRL-1573) and
glioma U87MG (ATCC HTB-14) were grown in DMEM
supplemented with 1 % nonessential amino acids, 1 % L-
glutamine, 100 IU/ml penicillin, 100 IU/ml streptomycin
and FBS (Sigma-Aldrich St. Louis, Mo, USA) 10 % or
0.2 % (serum starvation) at 37 °C in 5 % CO2 humidified
atmosphere in air. The cell lines used were obtained from
the American Type Culture Collection, Rockville MD,
USA. The primary lung tumour cells were grown in
DMEM-F12 [43]. The research protocol was approved by
ethic committee of S. Andrea Hospital, University of
Roma Sapienza. The study was conducted using C57BL/6
wild-type and Egr1 deficient mice (Egr-1−/−) [44]. Ani-
mals were housed four per cage. All the experiments were
performed in accordance with the EU Directive 2010/63/
EU for animal experiments and approved by ethic com-
mittee of Department of Medico-Surgical Sciences and
Biotechnologies, University of Roma Sapienza.
RT-qPCR
RNA extraction was performed after EGR1 silencing, B23
silencing and EGR1 overexpression into HeLa cells. For si-
lencing, EGR1 and B23 pre-designed siRNA (Invitrogen,
Grand Island, NY USA, 4390822) or scrambled sequence
RNA oligonucleotide (Negative Control siRNA 4390846)
were transiently transfected at 20, 30 nM or 60 nM using
High-Perfect Transfecting Agent (as indicated in the
figures) (Qiagen, Valencia, CA) following the Qiagen
protocol. The treatment with actinomycin D (Sigma) was
performed for 1 h at 37 ° C at the three concentrations
indicated in Fig. 2. The treatment with the proteasome
inhibitor MG-132 (Sigma) was performed at 37 °C for 16,
20 and 24 h during B23 silencing. For EGR1 overexpres-
sion pGFP-EGR1 expression vector [24] was transfected
using lipofectamin (Invitrogen, Grand Island, NY USA).
To analyse the levels of B23 in vivo, total RNA was ex-
tracted from female mice of wild type and Egr1 −/− mice.
Total RNA extraction and cDNA preparation were
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accomplished using RNeasy (Qiagen, Valencia, CA) and
Superscript III RT (Invitrogen, Grand Island, NY USA) ac-
cording to the manufacturer’s recommendations. For the
silencing and overexpression experiments we used the
protocols described previously [24]. Quantitative RT-PCR
was performed using Fast SYBR Green Master mix and
the StepOnePlus real-time PCR system (both from
Applied Biosystems). Each experiment was performed in
triplicate. Experiments were independently repeated three
times. Gene expression levels were quantified from real-
time PCR data by the comparative threshold cycle (CT)
method using 18S as an internal control gene. The follow-
ing gene-specific primers were used: B23: FW 5'-A
GAAAAAGCGCCAGTGAAGA-3’, REV 5’-TGGTGTT
GATGATTGGTTTTGA-3’ (for human gene), FW 5’-
GGGGGTACCGCTTTCTTTCAGGAGG-3’, REV 5’-CC
GCTCGAGGGCACGCACTTAGGTA-3’ (form mouse
gene); EGR1: FW 5’- AGCCCTACGAGCACCTGAC-3’
and REV 5’-GGTTTGGCTGGGGTAACTG-3’; 47S: FW
5’-TGTCAGGCGTTCTCGTCTC-3’ and REV 5’-GAGAG
CACGACGTCACCAC-3’. 18S: FW 5’-GCAATTATTCC
CCATGAACG-3’ and REV 5’-GGGACTTAATCAACG
CAAGC-3’; GAPDH: FW 5’-AGCCACATCGCTCAGA
CAC-3’ REV 5’-GCCCAATACGACCAAATCC-3’; p300:
FW 5’-GGTCAAGCTCCAGTGTCTCAA-3’ REV: 5’-GGG
ACTTAATCAACGCAAGC-3’. Each experiment of trans-
fection, immunoblotting and qPCR were repeated three
times in triplicate.
Immunoblotting
Immunoblotting analysis was performed using whole ex-
tracts (40 μg) from HeLa cells after silencing and overex-
pression of EGR1 [23], or B23 silencing. Total extract
(40 μg) were prepared from subconfluent cultures by
resuspending cells in RIPA-Buffer (20 mM Hepes, pH 6.8,
5 mM KCl, 5 mMMgCl2, 0.5 % NP-40, 0.1 % sodium. Fur-
thermore whole extracts (80 μg) were obtained from brain
of nine of wild type and Egr1 −/− female mice of three
months using RIPA buffer (20 mM Hepes pH 6.8, 5 mM
KCl, 5 mM MgCl2, 0,5 % NP-40, 0,1 % sodium deoxycho-
late, protease inhibitor (Sigma), 0.1 mM phenylmethylsul-
fonyl fluoride) using a Dounce homogenizer. After
incubation for 30 min at 0 ° C the lysate was centrifuged
at 10000 rpm × 15 min 4 ° C. The samples were loaded on
SDS-PAGE gel at 8 % or 10 % of acrylamide (Sigma 29:1)
and blotted on PVDF (Biorad) using a semidry apparatus
(Biorad). After blocking in 5 % dry milk the membrane
was incubated with the appropriate antibody. The primary
antibodies used are: rabbit polyclonal anti-EGR1 (sc-101,
Santa Cruz Biotechnology), mouse monoclonal antibody
anti-B23 (ab10530, Abcam), rabbit polyclonal antibody
anti-GAPDH (2118, Cell Signaling Technology Biotech-
nology) and monoclonal antibody anti-actin (sc-47778,
Santa Cruz). The secondary antibodies used for western
blot are anti-mouse and anti-rabbit (GE Healthcare
Bio-Sciences, Piscataway, NJ, USA). After ECL assay (GE
Healthcare) the membrane was incubated with film spe-
cific for protein detection (Kodak).
Luciferase and β–galactosidase activity assay
Cloning of the B23 minimal promoter To amplify the
proximal B23 promoter region, genomic DNA from
HeLa cells was used as template. The primers used are:
FW 5’-GGGGGTACCGCTTTCTTTCAGGAGGAAT-3’
REV 5’-CCGCTCGAGGGCACGCACTTAGGTAG-3’. To
verify the specificity of the PCR amplification, the fragment
obtained was excised from agarose gel and isolated using
DNA gel extraction kit (Millipore). The PCR product (re-
gion 4328 bp to 5240 bp of B23, NPM1, numatrin se-
quence; Accession: NG_016018) was KpnI/XhoI digested
and cloned into the pGL3 basic luciferase vector (Promega).
The correct sequence was checked by direct sequence
(Applied Biosystem). Site-specific mutations in the
EGR1-binding sites within the B23 promoter were made
with the QuickChangeII Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA). Briefly, primer sequences used to
generate point mutations are: FW 5’- GGAAGGAGGCTT
AAAGGAGGTAGAAAGGAGTG-3 REV 5’-CACTCCTT
TCTACCTCCTTTAAGCCTCCTTCC-3’. PCR reaction
conditions were: 95 °C for 1 min followed by 18 cycles
at 95 °C for 50 s, 60 °C for 50 s, 68 °C for 5 min, then
68 °C for 7 min. Following the PCR reaction, the mix
was digested by incubating with Dpn I for 1 h at 37 °C.
Clones of mutated plasmids were replicated in bacteria and
screened for the correct mutation by DNA sequencing (Ap-
plied Biosystem). Luciferase assay. HeLa cells were seeded
into 6-well plates and transfected with 0.3 μg trans-
activator plasmid pEgr1-GFP, 0.3 μg pB23-Luc or 0.3 μg
pB23-mut-Luc, plus 0.5 μg of β-galactosidase vector. At
24 h post-transfection, the levels of luciferase activity
were measured sequentially from a single sample using
the Luciferase reporter assay system (Promega) with a
luminometer (TD-20/20 Turner Design). Measurement
of luciferase enzyme activity was assayed on whole-cell
extract performed using 20 μl of lysate cleared and
100 μl of Luciferase assay Reagent. The luciferase values
were normalized to β-galactosidase activity and protein
content. The experiments of luciferase assay were repeated
three times in triplicate.
Chromatin immunoprecipitation (ChIP)
HeLa cells were transfected with full length EGR1
expression vector pEGFEGR1 or pEGFP empty vector
using lipofectamine 2000, fixed 48 h after transfection
with 1 % formaldehyde for 15 min at room temperature
and the reaction stopped by addition of 125 mM glycine
for 5 min. The other steps of the ChIP experiments were
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performed according to the manufacturer’s instructions
(Magna ChIP, Millipore). The extracts were immunopreci-
pitated with anti-EGR1 (4153, Cell Signaling Technology)
(24). The samples obtained were analysed by RT-qPCR
(Applied Biosystem) and standard PCR (Additional file 4:
Material and Methods) using specific couples of oligonu-
cleotides for B23 promoter. Primers used for PCR and real
time analysis are: FW 5’-TCGAGGTGCTCTCTGGCT
CAT-3’, REV 5’-TGCATAATGGCGTCGGCAG-3’ REV
5’-TGCATAATGGCGTCGGCAG-3’.
Statistical analysis
Each experiment was repeated at least three times. Stat-
istical comparisons were performed using Student’s t-test
and a one-way analysis of variance (ANOVA).
This research was supported by MIUR (PRIN 2011 Prot.
2010 ZEJWN_007) and University of Rome Sapienza
Ricerche Ateneo 2011–2014 to AC; Ateneo 2014 Prot. N.
0067282 to DP.
Additional files
Additional file 1: Figure S1. EGR1 levels are directly correlated to B23
expression in primary culture of lung adenocarcinoma tumor, kidney and
glioma cell lines under serum deprivation. In all these cultures the B23
mRNA underwent variations in their levels similar to those observed in
HeLa under the same experimental conditions. B23 synthesis at 0.2 % FBS
is significantly depressed following endogenous EGR1 silencing with
60 mM specific siRNA for lung adenocarcinoma (panel A), 30 nM specific
siRNA for U87MG (panel B) and 20 nM specific siRNA for 293 T (panel C).
The B23 expression does not change in scramble siRNA control. The data
shown are the mean of three independent experiments. Comparison
tests were performed by one way ANOVA. (** < p 0.01 *** < p 0.001).
(PSD 3175 kb)
Additional file 2: Figure S2. B23 nucleoplasm translocation in HeLa
cells after Actinomycin D treatment. Immunofluorescence analysis of B23
expression after actinomycin D treatment. (A) Control and (B) HeLa cells
treated (0,4 μg/ml) of HeLa cells for 1 h at 37 ° C. The images were taken
by under a 40X objective with immunofluorescence microscropy
(LEICADM4000B). (PSD 5029 kb)
Additional file 3: Figure S3. PCR analysis of ChIP samples. Analysis on
agarose gel of PCR amplification products of B23 promoter
immunoprecipitated with antibody to EGR1 from extracts of transfected
HeLa cells at 0.2 % FBS transfected with full length EGR1. (PSD 10140 kb)
Additional file 4: Materials and Methods: Immunofluorescence and
Standard PCR. (DOCX 16 kb)
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